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Abstract
Background: There is very small occurrence of adenocarcinoma in the small bowel. We present a case of primary
duodenal adenocarcinoma and discuss the findings of the case diagnostic modalities, current knowledge on the
molecular biology behind small bowel neoplasms and treatment options.
Case: The patient had a history of iron deficiency anemia and occult bleeding with extensive workup consisting of
upper endoscopy, colonoscopy, capsule endoscopy, upper gastrointestinal series with small bowel follow through
and push enteroscopy. Due to persistent abdominal pain and iron deficiency anemia the patient underwent push
enteroscopy which revealed adenocarcinoma of the duodenum. The patient underwent en-bloc duodenectomy
which revealed T3N1M0 adenocarcinoma of the 4th portion of the duodenum.
Conclusions: Primary duodenal carcinoma, although rare should be considered in the differential diagnosis of
occult gastrointestinal bleeding when evaluation of the lower and upper GI tract is unremarkable. We discuss the
current evaluation and management of this small bowel neoplasm.
Background
Malignancies of the small intestine are uncommon,
accounting for only roughly 1-2 % of malignant gastro-
intestinal (GI) diseases [1]. When compared to other
cancer diagnosis rates, small bowel cancers average
roughly 6000 per year in the United States [2]. As sug-
gested by two recent major epidemiological studies on
patients with small bowel neoplasms (SBN) identified
from the National Cancer Data Base (NCDB, 1985-
2005) and the Surveillance Epidemiology End Results
(SEER, 1973-2004) database [3] as well as the Connecti-
cut Tumor Registry [4], over the past twenty years, car-
cinoid tumors have become the most common SBN
followed by adenocarcinomas (AC). A significant obser-
vation based on these studies is that from 1973 to 2004,
the incidence of carcinoid tumors increased more than
4-fold (2.1 to 9.3 per million), with similar increases in
the incidence of AC, stromal tumors, and lymphomas
[3]. While AC is the most common malignancy of the
duodenum the most common site of SBN is the ileum
(Table 1), with a preponderance of lymphoma and carci-
noids [5]. Among patients with Crohn’s disease AC is
most noted in ileum rather than the more proximal
small bowel [6]. AC of the 3
rd and 4
th portions of the
duodenum is very uncommon [7], and only 45% of duo-
denal carcinomas occur in that region [8].
The low incidence of SBN may be due to several theo-
retical factors including small bowel transit time, host
immunologic factors, and/or epithelial toxin exposure
[9-11]. Dietary factors that may increase the risk of
small bowel AC may include diets high in red meat, or
the consumption of smoked or salted foods [12]. There
may be an increased risk of SBN with a diet rich in
refined carbohydrates, and sugar [13]. Hereditary syn-
dromes or conditions that can predispose to SBN
include Muir-Torre syndrome [14], hereditary nonpoly-
posis colorectal cancer (HNPCC), familial adenomatous
polyposis (FAP) and it’sv a r i a n t ss u c ha sG a r d n e r ’s Syn-
drome [15] Celiac Sprue, Puetz-Jeghers, Crohn’s Disease
[16] and Juvenile Polyposis Syndrome [17].
Primary SBNs are much rarer than those that arise
from a secondary neoplastic process [16]. Metastasis
from the stomach, ovary, colon and uterus can involve
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vement [18]. Metastatic tumors from breast, melanoma
and lung appear to spread to the duodenum by blood
and lymphatic pathways.
The mean age of presentation of SBN is 64 with a
range of 47-87 years [3,19]. Obscure GI bleeding (OGIB)
is the most common symptom as 50% of those with SBN
present with OGIB, however it should be noted that only
4% of OGIB cases are caused by SBN [20]. Due to the
vague presentation a delayed diagnosis or misdiagnosis is
common [9], with an average delay of six to eight months
between the time of symptom onset and diagnosis [21].
Investigations
SBN are usually discovered during the evaluation of
OGIB, anemia, and abdominal pain. Abdominal X-ray
may help in showing obstruction, however duodenal car-
cinomas especially those in the 3
rd and 4
th portions of
the organ are often missed on barium x-ray examination
[22] yielding a definite diagnosis in less than 5% of cases
[23]. Colonoscopy with ileoscopy may be useful in detect-
ing lesions in the terminal ileum and excluding a colonic
source of pathology. Both sporadic duodenal adenomas
and those associated with hereditary cancer syndromes
have a higher risk of colorectal cancer (CRC) and these
patients should be evaluated with colonoscopy [24]. Like-
wise those with CRC associated with hereditary cancer
syndromes should be evaluated for SBN [17].
The utilization of CT enterocolysis (CTE) in the
detection of SBN overcomes the individual short com-
ings of both barium enterocolysis and conventional CT
and utilizes the advantages of both into a single techni-
que and has begun to substitute enterocolysis in clinical
practice [25]. Contrast-enhanced and water-enhanced
multidetector CTE has a sensitivity of 84.7-95% and 96-
100 % specificity for the detection of SBN [26,27].
Tocchi et al. found that upper GI endoscopy had a
36% false-negative result rate in identifying duodenal
tumors due to depth of insertion. Push enteroscopy (PE)
provides many benefits including direct visualization of
Table 1 Accumulating reports on the incidence of small bowell malignancies: type, location and survival rates
Incidence (%) of small bowel malignancy based on histology
Adenocarcinoma Carcinoid
Tumors
Lymphoma Sarcoma Reference
40 25 25 10 [69]
47 28 12 13 [70]
40 20 27 9 [71]
36.9 37.4 17.3 8.4 [4]
27 33 16.3 7.1 [3]
Incidence (%) of small bowel adenocarcinoma based on location
Duodenum Jejunum Ileum Reference
72 37 21.4 [69]
47 29 24 [70]
41 34 25 [71]
56 15.6 13 [4]
53 19.7 12.9 [3]
Incidence (%) of small bowel tumors by location
Duodenum Jejunum Ileum Reference
24.6 36.9 38.3 [69]
32 36 32 [70]
23 33.3 41.6 [71]
33 12 26 [4]
25 15.3 29.7 [3]
Five year survival rate (%) of small intestine adenocarcinoma based on disease stage [2]
Stage I 55
Stage II A 49
Stage II B 35
Stage III A 31
Stage III B 18
Stage IV 5
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ing the ability to biopsy and provide therapeutic mea-
sures in cases of bleeding. The investigation of obscure
bleeding by PE may find a diagnostic cause in 25-28% of
cases [28,29]. PE and Sonde enteroscopy have shown a
diagnostic yield of 6% for SBN in patients undergoing
the procedure for evaluation of OGIB [30]. However PE
as well as CT and small bowel barium studies may fail
to detect 50% of small bowel lesions [31].
Capsule endoscopy (CE) has been shown to be a safe
and effective non invasive method of diagnosis for small
bowel abnormalities [32,33] and allows a more detailed
inspection of the small intestine. CE has also been
shown to detect duodenal adenomatous polyps in 64.3%
of those who also have FAP [34]. An absolute contrain-
dication to CE is GI obstruction. Relative contraindica-
tions to CE include pregnancy, GI motility disorders, or
large diverticuli within the small bowel [35]. CE may
detect more SBN than CTE in patients with OGIB hav-
ing an overall accuracy of 84.7%[36].
It has been shown that CE diagnosed SBN in 9% of
patients who underwent the procedure for investigation
of OGIB and in 8.3% of those who were investigated for
non bleeding causes [37]. However in a pooled meta-
analysis it was found that CE had a 20% miss rate for
SBN [38]. Similar to our case where CE failed to reveal
AC of the duodenum, there are increasing reports in the
literature of failure of CE to detect solitary SBN [39,40].
It has also been shown that after an initial negative CE
study a repeat CE may reveal significant lesions in 20%
of cases [41]. Etiologies for failure to detect lesions by
CE may be due to rapid capsule passage through the
proximal small bowel, decreased visibility due to luminal
contents, or failure to reach the colon. Thus, based on
certain clinical scenarios a negative finding on CE may
not exclude significant small bowel pathology and
further investigation may be warranted.
Balloon assisted enteroscopy (BAE) utilizing either sin-
gle balloon enteroscopy (SBE) or double balloon entero-
scopy (DBE) offers a number of advantages when
compared to other small bowel imaging studies. The
advantages include visualization of the entire small
bowel with the ability to provide tissue diagnosis and
provide therapeutic modalities such as control of bleed-
ing and dilation of strictures [42,43]. Optimal visualiza-
tion of the small bowel may involve both oral and anal
insertion. Initial studies indicated a greater diagnostic
yield and higher rate of endoscopic intervention for
DBE vs. SBE[44]. However a recent study comparing
SBE vs DBE revealed identical procedure times, depth of
insertion, and a slight increase in identification and
treatment of lesions with SBE vs DBE[45]. Studies have
calculated that BAE and CE are in agreement 61-74% of
the time and 96% of the time when diagnosing large
tumors [46]. In regards to SBN, BAE can often find
lesions originally missed by CE and is suggested as a fol-
low up study to a negative CE exam [47]. Arakawa
reported equal diagnostic yields for both CE and BAE
with false negative cases of CE and BAE due to failure
to detect lesions in the proximal small bowel and inac-
cessibility of the site, respectively. In a recent meta-ana-
lysis comparing CE and BAE, there was no significant
difference in yields between the two modalities 61% vs.
56%, respectively[48]. Sub analysis of data did reveal a
slight advantage in favor of CE and this appeared to be
to the utilization of a single insertion approach by BAE.
When BAE was performed using a dual insertion
approach via the oral and anal route the yield was 74%
vs. 54% for CE [48].
The failure of BAE to show superiority over CE in the
detection of lesions may be due to complete evaluation
of the entire small bowel in only 60-70% of cases
[43,49]. A disadvantage of the procedure is the time
needed to visualize the small bowel [50], its invasiveness,
and the reports of intestinal necrosis [51], perforation
and acute pancreatitis [52] post procedure. Due to the
failure of a true gold standard in evaluation of the small
bowel utilization of both these procedures may be
complementary.
Treatment and Prognosis
Duodenal AC has a shorter median overall survival rate
compared with patients with tumors located in the jeju-
num or ileum [53]. SBNs are more common in men
[54] and are higher in African Americans than those of
Caucasian decent. It has been reported that SBN in Afri-
can American men has increased in prevalence by 120%
over the last 3 decades [55]. In regards to 5 year survi-
val, earlier stages have a better prognosis [56]. Around
58% of patients with small intestine AC present at late
stages (III and IV), in contrast with 28% of patients with
CRC[55] (Table 1). The overall median survival of
patients with duodenal AC has been reported as
18 months and the 5-year survival as 23% [57].
Historically treatment of SBN has relied solely upon
surgery as the only curative treatment and has been
divided between two techniques which are pancreato-
duodenectomy (PD) and duodenal segmentectomy (DS).
PD is considered to be the procedure of choice. DS, is
used for more palliative measures [8]. Studies have
shown that DS is a better option for distal duodenal
tumors without advanced disease, in which case PD is
considered a better option [8,57,58]. Surgical interven-
tion has shown to provide a curative resection in
40-65% of patients. The five year survival rate for non-
resected tumors being is 15-30% compared to 40-60%
survival rate for those who had resection [53]. A large
tumor or positive lymph node metastasis does not
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attained, and in terms of clearance of regional lymph
nodes the difference between both procedures is negligi-
ble [57].
Chemotherapy is mainly utilized as a palliative mea-
sure and has not been well studied due to the low pre-
valence of AC in the small bowel. The largest published
study investigating chemotherapeutic measures for small
bowel AC involved 14 subjects with metastatic small
bowel AC and involved a chemotherapeutic regiment
containing 5-fluorouracil (5-FU) [59]. Patients had a
median survival of 9 months. A more recent investiga-
tion reported advanced small bowel AC treated with
infusional 5-FU-based regimens had a response rate of
37.5% and a median survival of 13 months [60]. A case
report using onastat, tegafur, and gimestat (otherwise
known as S-1chemotherapy) showed remission of pri-
mary AC of the duodenum [61]. Newer agents found to
be effective for CRC also may have an effect on small
bowel AC.
Genetic and Molecular Biology Considerations
Due to the rarity of SBN, little has been published about
oncogenesis as well as clinicopathologic features [62].
An analysis of SBN found that 53% had point mutations
in the Ki-ras gene [63] similar to mutations found in
CRC[64], and that overall frequencies of Ki-ras and p53
gene mutations are similar in both [63].
In terms of the APC gene, SBN have a lower rate of
mutations involving the APC gene compared to its
involvement in CRC [63]. Duodenal carcinoma is the
second most common carcinoma in FAP and the low
rate of APC mutations in duodenal adenocarcinoma
refer primarily to sporadic adenocarcinomas and not
those associated with FAP and its variants. Thus these
recent findings suggest that the APC gene is not
involved with SBN in man [63,65]. An extensive study
revealed all duodenal AC tumors to be positive for mis-
match repair (MMR) on genes hMHL1 and hMSH2 but
no mutations were found in the mutation cluster region
(MCR) of the APC gene [66]. Thus suggesting that
molecular mechanism leading to the development of AC
of the small intestine may be different than those lead-
ing to CRC. Cytogenetical studies on primary duodenal
AC revealed several abnormalities that resulted in partial
or complete losses or gains chromosomally [67]. The
detection of biallelic MMR gene mutations in pediatric
duodenal cancer further supports the idea of MMR defi-
ciencies as a duodenal cancer predisposition syndrome
[68].
Case Presentation
A 66 year old African-American female presented with
complaints of 10 pound weight loss and a four week
history of intermittent abdominal pain, nausea, and non
bloody emesis. Her medical history was significant for
type 2 diabetes mellitus, hypertension, coronary heart
disease, and peptic ulcer disease. The patient denied any
significant alcohol or tobacco use. Her family history
was positive for colon cancer. Physical exam and labora-
tory tests were unremarkable. A colonoscopy and an
esophagogastroduodenosopy (EGD) to the second por-
tion of the duodenum were performed revealing three
small tubular adenomas of the colon and helicobacter
pylori gastritis. She was treated with two weeks of
amoxicillin 1 gram and clarithromycin 500 mg orally
twice daily for two weeks.
She did well after the antibiotic therapy and was not
seen again until two years later when she was hospita-
lized for severe, symptomatic anemia. For eight months
prior to admission, she noted recurrent intermittent
abdominal pain and nausea with non-bloody emesis and
progressive fatigue. She denied melena or hematochezia.
On admission, her hemoglobin was 5.4 gm/dl and
hematocrit was 17.3%, with a normal MCV. Her stool
was hemoccult positive. She required a transfusion of
four units of packed red blood cells. An EGD to the sec-
ond portion of the duodenum revealed mild gastritis,
negative for H. pylori. A CT scan of the abdomen and
pelvis with oral contrast was unremarkable. An outpati-
ent wireless capsule endoscopy was ordered; however, it
was cancelled due to the reluctances of the patient to
swallow the capsule.
Patient again required hospitalization for severe symp-
tomatic anemia with hemoglobin of 5 gm/dl. Her
indices and iron studies at this time were consistent
with iron deficiency anemia. She denied melena, hema-
tochezia or bloody emesis. She required another 4 unit
blood transfusion. An EGD was performed and again it
was unremarkable. Due to her inability to swallow the
wireless capsule, the endoscope was used to deliver the
capsule into the stomach. The study however was lim-
ited due to retained debris in the mid duodenum, signif-
icantly limiting visualization of the small bowel.
Patient presented three months later with sympto-
matic anemia, hemoglobin of 4.6 gm/dl and hematocrit
of 14.2%. She required four units of packed red blood
cells. Two days prior to admission, she noted black tarry
stools. Physical exam was unremarkable with the excep-
tion of palpable tenderness in the epigastric and left
upper quadrant.
Three way abdominal x-ray of the abdomen was per-
formed and was unremarkable. MRA with and without
contrast and CT scan of abdomen and pelvis with oral
contrast showed no evidence of localized abnormality in
the abdomen or pelvis in terms of solid organs or vascu-
lature. An upper GI series with KUB was performed
revealing eccentric broadband defect along the inner or
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the other portions being unremarkable.
Push enteroscopy was performed which revealed a cir-
cumferential fungating mass in the 4th portion of the
duodenum, which was actively oozing blood and upon
further investigation it appeared the mass extended to
the ligament of Treitz (Figure 1). The area was biopsied
and tattooed. Pathology from biopsy revealed moder-
ately differentiated AC with lymphovascular invasion.
Patient underwent exploratory laparotomy and the small
bowel was examined with the tumor being present at
the ligament of Treitz. The tumor was resected en bloc
and two lymph nodes were collected. The small bowel
was reconnected using a primary Gambee anastamosis.
Pathology from surgical specimen revealed T3N1M0
AC, with the tumor being 4.5 centimeters in greatest
dimension and showing invasion through the muscularis
propria and into the sub-serosa but not through it. The
resected margins were clear. Of the two lymph nodes col-
lected one was positive for metastatic carcinoma, with
the tumor nodule measuring 1.5 centimeters in diameter
and showing invasion through the lymphatic capsule.
Patient was referred to oncology for consultation how-
ever did not follow up as scheduled, and has been lost
to follow up care.
Conclusions
In patients presenting with OGIB, iron deficiency ane-
mia or other warning signs and symptoms SBN, should
be considered in the differential due to its insidious pre-
sentation. In terms of oncogenesis more research is
needed in order to better understand its development,
but evidence suggests a multi-factorial genetic cause.
Options in the evaluation of small bowel pathology may
require CE, BAE, and/or CTE. An initial approach may
be with CE or CTE due to the fact it is non invasive
with subsequent utilization of BAE if the evaluation is
unrevealing or if lesions are detected that require tissue
confirmation. Surgery is the best curative option in
terms of treatment of these types of malignancies with
PD being better for advanced diseases and DS for dis-
ease of the distal duodenum. Chemotherapeutic options
are improving and providing longer survival rates and
palliative benefits.
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